Public Release:  £3.2M to improve diagnosis of cancer

University of Liverpool

The University of Liverpool has been awarded £3.2 million to develop new diagnostic tests for cervical, oesophageal and prostate cancer patients.

These cancers are difficult to detect at an early stage as symptoms only become apparent when the tumours become large.

Research at Liverpool has already shown that infra-red electron laser technology could diagnose the presence of oesophageal cancer, but more work is needed to understand the changes within individual cells prior to cancer development.

Funding from the Engineering and Physical Sciences Research Council (EPSRC) will allow researchers to use a unique and extremely intense source of infrared light (the Infrared Free Electron Laser) using the Science and Technology Facilities Council's ALICE facility to identify changes within and surrounding cells which indicate a tumour. They will develop equipment in the terahertz region of the electromagnetic spectrum to facilitate the design of cheap portable instruments for cancer diagnosis.

Liverpool Professor of Physics, Peter Weightman, said: "Researchers in clinical and physical sciences are exploring how to identify, at a very early stage, the chemical changes in cells which lead to the development of cancer.

"The funding will allow us to further develop, test and apply our diagnostic technique to cervical and prostate cancers. Early diagnosis is the most important thing when treating cancers and we hope this new technique will result in new instrumentation that will directly benefit patients."

Gastric cancer specialist, Professor Andrea Varro, from the University's Institute of Translational Medicine, said: "The technology we are using provides a unique opportunity to detect alterations in both cancer and the surrounding stromal cells which indicate tumour progression, thereby helping diagnosis and the development of therapies."

###

Partners in the project include Cardiff University, the universities of Lancaster and Manchester; the Royal Liverpool and Broadgreen University Hospitals NHS Trust; the Christie NHS Foundation Trust; and the Lancashire Teaching Hospitals NHS Foundation Trust.

Notes to editors:

1. ALICE (Accelerators and Lasers In Combined Experiments) is a test accelerator facility located at the Science and Technology Funding Council's Daresbury Laboratory in Cheshire.

2. The University of Liverpool is one of the UK's leading research institutions with an annual turnover of £420 million, including £150 million for research. Liverpool is ranked in the top 1% of higher education institutions worldwide and is a member of the Russell Group. Visit http://www.liv.ac.uk or follow us on twitter at: http://www.twitter.com/livuninews

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.